CVM

AMEX

CEL-SCI

$2.13
-0.61 (-22.26%)
2026-10-07 00:00
Healthcare Biotechnology
-- --

Short Interest (1 Year)

% of Volume Sold Short
Market Cap
$29.2M
P/E Ratio
N/A
52W Low 52W High
$0.89 $10.39
Volume
661K
Analyst Rating
Hold
Target: $21

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Website cel-sci.com

Financial Highlights

Annual Quarterly
Year Revenue Op Margin Net Income Free Cash Flow
2025 N/A N/A% -$25.4M -$17.1M
2024 N/A N/A% -$26.9M -$18.7M
2023 N/A N/A% -$32.4M -$22.5M
2022 N/A N/A% -$36.7M -$17.6M
2021 N/A N/A% -$36.4M -$9.7M